{"id":"NCT01640951","sponsor":"Novartis Pharmaceuticals","briefTitle":"4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis","officialTitle":"A Multicenter, Double-blind and Open Label, 4 Year Extension Study of Subcutaneous Secukinumab in Prefilled Syringes, Assessing Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Treated With Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09-16","primaryCompletion":"2017-05-04","completion":"2017-05-04","firstPosted":"2012-07-16","resultsPosted":"2018-05-25","lastUpdate":"2018-05-25"},"enrollment":675,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Chronic Plaque-Type Psoriasis"],"interventions":[{"type":"DRUG","name":"AIN457 150 mg","otherNames":["Secukinumab 150 mg"]},{"type":"DRUG","name":"AIN457 300 mg","otherNames":["Secukinumab 300 mg"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AIN457 150 mg - Fixed Interval (FI)","type":"EXPERIMENTAL"},{"label":"AIN457 150 mg - Start of relapse (SoR)","type":"EXPERIMENTAL"},{"label":"AIN457 300 mg - Fixed Interval (FI)","type":"EXPERIMENTAL"},{"label":"AIN457 300 mg - Start of Relapse (SoR)","type":"EXPERIMENTAL"},{"label":"AIN457 300 mg - Open Label (OL)","type":"EXPERIMENTAL"}],"summary":"CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of secukinumab in both the fixed interval regimen and the retreatment at start of relapse regimen. All subjects who completed the full study treatment period (52 weeks) in the cores studies CAIN457A2304 and CAIN457A2307 were eligible to participate in this extension study. In this extension study, the prefilled syringe (PFS) liquid formulation of secukinumab was used.","primaryOutcome":{"measure":"Long-term Safety and Tolerability of Secukinumab","timeFrame":"Week 268","effectByArm":[{"arm":"AIN150FI","deltaMin":88.3,"sd":null},{"arm":"AIN150 FI_AIN300 FI","deltaMin":92,"sd":null},{"arm":"AIN300 FI","deltaMin":92.9,"sd":null},{"arm":"AIN150 SoR","deltaMin":78.2,"sd":null},{"arm":"AIN150 SOR_AIN300 FI","deltaMin":87.4,"sd":null},{"arm":"AIN300 SoR","deltaMin":80,"sd":null},{"arm":"AIN300 SoR _ AIN300 FI","deltaMin":94.6,"sd":null},{"arm":"AIN300 OL","deltaMin":93.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":111,"countries":["United States","Austria","Bulgaria","Canada","Czechia","France","Germany","Italy","Japan","Poland","Singapore","Slovakia","Switzerland","United Kingdom","Vietnam"]},"refs":{"pmids":["28580579"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":132},"commonTop":["NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","ARTHRALGIA","HYPERTENSION","BACK PAIN"]}}